<DOC>
	<DOCNO>NCT00719472</DOCNO>
	<brief_summary>This prospective , open-label , Phase III , multicenter , single-arm trial design assess safety , pharmacokinetics , pharmacodynamics alternative dose rate rituximab previously untreated patient diffuse large B-cell lymphoma ( DLBCL ) follicular non-Hodgkin lymphoma ( NHL ) .</brief_summary>
	<brief_title>A Study Rituximab Alternative Dosing Rate Patients With Previously Untreated Diffuse Large B-cell Follicular Non-Hodgkin 's Lymphoma ( RATE )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antipyretics</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Written inform consent Age ≥ 18 year Patients previously untreated diffuse large Bcell lymphoma ( DLBCL ) schedule receive rituximab 375 mg/m^2 plus CHOP ( cyclophosphamide , hydroxydaunorubicin [ also call doxorubicin adriamycin ] , Oncovin [ vincristine ] , prednisone prednisolone ) chemotherapy , previously untreated follicular nonHodgkin lymphoma ( NHL ) schedule receive rituximab 375 mg/m^2 plus CVP ( cyclophosphamide , vincristine , prednisolone ) chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 02 * Clinically significant cardiovascular disease ( eg , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Classification Grade II great congestive heart failure , ventricular arrhythmia require medication within 1 year prior Day 1 , NYHA Grade II great peripheral vascular disease Day 1 ( first day treatment ) Patients meet follow criterion exclude study participation Cycle 1 : Circulating lymphocyte count &gt; 5,000/μL Cycle 2 rituximab infusion Development serious and/or Grade 3 4 adverse event Cycle 1 judge investigator related rituximab infusion Prior premedication additional corticosteroid prednisone include chemotherapy regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Follicular NHL</keyword>
	<keyword>NHL</keyword>
	<keyword>Large B-Cell NHL</keyword>
</DOC>